Seqirus

Seqirus, established in 2015, is a prominent global leader in influenza vaccines, dedicated to safeguarding public health and ensuring pandemic preparedness. The company leverages extensive research and advanced manufacturing expertise to develop robust solutions against influenza epidemics and pandemics. With a heritage spanning over a century, Seqirus actively collaborates with international health organizations to implement effective vaccination strategies, serving communities and health bodies worldwide. Its core mission revolves around the prevention and treatment of influenza, utilizing state-of-the-art biopharmaceutical and biotechnology capabilities. The company operates within a competitive landscape, facing entities like Merck Sharp & Dohme, Sanofi Pasteur, and Dynavax Technologies.

The organization's operational scope includes a sophisticated global manufacturing network designed for both routine influenza prevention and rapid response during public health crises. Seqirus is committed to innovation in vaccine development and production, often engaging in public-private partnerships to enhance its capabilities. The company's scale is reflected in its employee range of 1,000-5,000 individuals, indicating a significant workforce dedicated to its mission. For insights into the people driving this mission, one can Meet Seqirus's team to understand their leadership and operational structure.

Seqirus generates substantial revenue, reported at $251.4M, underscoring its significant market presence and financial capacity within the biopharmaceutical sector. The company's product portfolio primarily centers on influenza vaccines, crucial for global health security. Its strategic focus on public health protection positions it as a key player in the biopharmaceutical industry, contributing to disease prevention and preparedness on a global scale. The company's commitment to innovation and collaboration reinforces its roleView more...